Recombinant SARS-CoV-2 Nucleocapsid 抗体 (Whole Molecule)
-
- 抗原 See all SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N) 抗体
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
- 抗体类型
- Recombinant Antibody
-
抗原表位
- Whole Molecule
-
适用
- SARS Coronavirus-2 (SARS-CoV-2)
-
宿主
- 小鼠
- Expression System
- Phage display
-
克隆类型
- 单克隆
-
标记
- This SARS-CoV-2 Nucleocapsid antibody is un-conjugated
-
应用范围
- ELISA, Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS)
- 原理
- recombinant anti-SARS-CoV-2 Nucleocapsid protein antibody
- 特异性
- This is an antibody developed by antibody phage display technology using a human naive antibody gene library and SARS-CoV-2 antigen. For this antibody both the heavy and light chains are cloned and expressed, generating full-length antibodies.
- 交叉反应 (详细)
- SARS-CoV1 N-protein
- 产品特性
- This antibody can be detected with anti-mouse Fc secondary antibodies.
- 纯化方法
- Protein A purification
- 质量等级
- Animal-Free
- 免疫原
- No immunization, animal-free antibody development. Antigen: Nucleocapsid protein: MSDNGPQSNQRSAPRITFGGPTDSTDNNQNGGRNGARPKQRRPQGLPNNTASWFTALTQHGKEELRFPRGQGVPINTNSGPDDQIGYYRRATRRVRGGDGKMKELSPRWYFYYLGTGPEASLPYGANKEGIVWVATEGALNTPKDHIGTRNPNNNAATVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRGNSRNSTPGSSRGNSPARMASGGGETALALLLLDRLNQLESKVSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKQYNVTQAFGRRGPEQTQGNFGDQDLIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYHGAIKLDDKDPQFKDNVILLNKHIDAYKTFPPTEPKKDKKKKTDEAQPLPQRQKKQPTVTLLPAADMDDFSRQLQNSMSGASADSTQA
- 克隆位点
- AB79-E11
- 亚型
- IgG2a
- Top Product
- Discover our top product SARS-CoV-2 N Primary Antibody
-
-
- 应用备注
- Western Blot: 0.2-5 μg/mL ELISA: 1-12 μg/mL as coating antibody 0.5-5 μg/mL as detection antibody IF: 0.1 - 10 μg/mL Optimal working dilution should be determined by the investigator
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4,
- 储存条件
- -20 °C
-
- 抗原
- SARS-CoV-2 Nucleocapsid (SARS-CoV-2 N)
- 别名
- SARS-CoV-2 Nucleocapsid protein (NP) (SARS-CoV-2 N 产品)
- 背景
- Coronaviruses (CoVs) are enveloped non-segmented positive-sense single-stranded RNA viruses and can infect respiratory, gastrointestinal, hepatic and central nervous system of human and many other wild animals. Recently, a new severe acute respiratory syndrome β-coronavirus called SARS-CoV-2 (or 2019-nCoV) has emerged, which causes an epidemic of acute respiratory syndrome (called coronavirus human disease 2019 or COVID-19). SARS-CoV-2 shares 79.5 % sequence identity with SARS-CoV and is 96.2 % identical at the genome level to the bat coronavirus BatCoV RaTG133, suggesting it had originated in bats. SARS-CoV-2 contains 4 structural proteins, including Envelope (E), Membrane (M), Nucleocapsid (N) and Spike (S), which is a transmembrane protein, composed of two subunits S1 and S2. The S protein plays a key role in viral infection and pathogenesis. The S1 subunit contains the N-terminal domain (NTD) and a receptor binding domain (RBD), which binds to the cell surface receptor Angiotensin-Converting Enzyme 2 (ACE2) present at the surface of epithelial cells, causing mainly infection of human respiratory cells, whereas S2 harbors heptad repeat 1 (HR1) and HR2. The RBD domain first binds its receptor to form an RBD/ACE2 complex. This triggers conformational changes in the S protein, leading to membrane fusion mediated via HR1 and HR2 and consequently in viral entry into target cells. Antibodies targeting various regions of S protein have different mechanisms in inhibiting SARS-CoV-2 infection. For example, NTD-targeting antibodies bind the NTD to form an NTD/mAb complex, thereby preventing conformational changes in the S protein and blocking membrane fusion and viral entry. RBD-targeting antibodies form RBD/mAb or RBD/Nb complexes that could inhibit binding of the RBD to ACE2, thereby preventing entry of SARS-CoV-2 into target cells.
- 分子量
- 25 kDa
- NCBI登录号
- NP_828858
- UniProt
- P59595
-